Literature DB >> 3581071

Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans.

R R Eger, D G Covell, J A Carrasquillo, P G Abrams, K A Foon, J C Reynolds, R W Schroff, A C Morgan, S M Larson, J N Weinstein.   

Abstract

Using data from 12 patients, we have analyzed the pharmacokinetics of 111In-9.2.27, an antimelanoma monoclonal antibody, following i.v. infusion. Plasma data and scintillation camera images obtained from patients receiving either 1, 50, or 100 mg of monoclonal antibody indicated dose-dependent (i.e., saturable) kinetics. Based on these observations and known immunoglobulin kinetics, we developed a nonlinear compartmental model to describe the biodistribution of 111In-9.2.27 and the other coinjected 111In-associated compounds. The model included (a) three compartments representing intact 111In-9.2.27 ("plasma," "nonsaturable," and "saturable binding" compartments), (b) four compartments representing 111In-diethylenetriaminepentaacetic acid, and (c) one compartment representing 111In in an undetermined chemical form ("extravascular delay" compartment). Analysis of the rate of urinary excretion relative to plasma concentration indicated that the saturable binding compartment was a site for catabolism of monoclonal antibody. Further examination of the urinary data, together with previous studies of the site(s) of immunoglobulin catabolism, suggested that additional elimination took place from either the plasma or the nonsaturable compartment. The model indicated that to fill the saturable sites would require a dose of approximately 0.5 mg and suggested that greater than 3.5 mg would maintain saturation for 200 h. Computer integration of gamma camera counts over the spleen revealed a clear saturable component of uptake, whereas integration over the liver showed no such pattern. The proposed model was fitted to the liver and spleen imaging data by summing fractions of model simulations of each compartment. That analysis confirmed the suspected saturable uptake by the spleen (21% of the saturable binding compartment) and revealed a quantitatively important component of saturation in the liver (35% of the saturable binding compartment) that was not obvious from initial examination of the images. When the results were expressed on a concentration basis, the spleen accounted for 247% of the saturable compartment per kg, whereas the liver accounted for 25%/kg. The bone marrow also showed saturable uptake; hence, the saturable uptake may relate to the sinusoidal blood supply characteristic of liver, spleen, and marrow. The model predicts the dose levels required to overcome saturable background, suggests appropriate doses and schedules for cold loading strategies, and provides a format for explicit inclusion of tumor antigen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581071

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Optimal tumor targeting by antibodies: development of a mathematical model.

Authors:  M J Chappell; G D Thomas; K R Godfrey; A R Bradwell
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

Review 2.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Measurement of mass transport and reaction parameters in bulk solution using photobleaching. Reaction limited binding regime.

Authors:  E N Kaufman; R K Jain
Journal:  Biophys J       Date:  1991-09       Impact factor: 4.033

4.  Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.

Authors:  Peter Kletting; Christoph Meyer; Sven N Reske; Gerhard Glatting
Journal:  Cancer Biother Radiopharm       Date:  2010-06       Impact factor: 3.099

5.  Equilibrium and kinetic parameters for the interaction of a monoclonal antibody with liposomes bearing fluorescent haptens.

Authors:  A Petrossian
Journal:  Cell Biophys       Date:  1993 Aug-Dec

6.  Antibody transport and internalization into tumours.

Authors:  S Matzku; G Moldenhauer; H Kalthoff; S Canevari; M Colnaghi; J Schuhmacher; H Bihl
Journal:  Br J Cancer Suppl       Date:  1990-07

7.  Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.

Authors:  Ping He; Kim Kramer; Peter Smith-Jones; Pat Zanzonico; John Humm; Steven M Larson; Nai-Kong V Cheung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-09       Impact factor: 9.236

8.  A preliminary pharmacokinetic study of 111In-labeled 260F9 anti-(breast cancer) antibody in patients.

Authors:  T W Griffin; F Bokhari; J Collins; M Stochl; M Bernier; M Gionet; D Siebecker; M Wertheimer; E S Giroves; L Greenfield
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption.

Authors:  C Hartmann; D C Bloedow; D G Dienhart; R Kasliwal; T K Johnson; R Gonzalez; P A Bunn
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

Review 10.  Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates.

Authors:  Michael Ritchie; Lioudmila Tchistiakova; Nathan Scott
Journal:  MAbs       Date:  2012-12-06       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.